Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients

Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01072708

Acronym

DIAMUCO

Enrollment

230

Registered

2010-02-22

Start date

2009-04-30

Completion date

2014-10-31

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes in Cystic Fibrosis Patients

Keywords

Cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors

Brief summary

For some years, the investigators observe an increase of the arisen of diabetes in cystic fibrosis patients However, this diabetes may be reversible. The investigators speak about Cystic fibrosis related diabetes.. The objective of this project, is to know better what facilitates the appearance and the reversibility of the diabetes, such as the genetic mutations, the respiratory state and the lung infections. Theses knowledges should allow to adapt the screening of diabetes, and its treatment, for the patients affected by cystic fibrosis.

Interventions

OTHERProspective cohort with an annual follow-up

Annualfollow-up including : * oral glucose tolerance test * dietary survey * biological evaluation * bacteriological and respiratory measures * dual-energy x-ray absorptiometry * physical activity survey

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

10 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Cystic fibrosis patients with at least one visit in Cystic fibrosis Center in Rhône-Alpes (France) during the second half-year 2008 * Patients with disorders or not of the glucose metabolism * Patient with pancreatic insufficiency

Exclusion criteria

* Patient with hypoglycemia treatment : insulin or oral antidiabetic * Patient with an age \< 10 years * Patient with lung transplant

Design outcomes

Primary

Measure	Time frame
Describe the natural history of the glucose tolerance in cystic fibrosis patients and to identify the predictive factors of the reversibility or the aggravation in the disorders of the glucidic metabolism.	3 years

Secondary

Measure	Time frame
Estimate prevalence of the various stages of disorders of the glucose metabolism : glucose intolerance and diabetes	3 years
Estimate the probability of arisen the complications associated to the disorders of the glucidic metabolism : - deterioration of the respiratory function, - lung exacerbations - alteration of the nutritional state	3 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026